trending Market Intelligence /marketintelligence/en/news-insights/trending/lisy5eoqeisauferoy0s_g2 content esgSubNav
In This List

Arrowhead gets US FDA orphan drug status for liver disease drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Arrowhead gets US FDA orphan drug status for liver disease drug

The U.S. Food and Drug Administration granted orphan drug designation to Arrowhead Pharmaceuticals Inc.'s investigational medicine ARO-AAT to treat a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

Alpha-1 antitrypsin deficiency, A1AD or AATD, is a genetic disorder that may result in lung disease or liver disease.

Pasadena, Calif.-based Arrowhead filed a clinical trial application in December 2017, requesting regulatory permission to begin first-in-human studies of the drug.